NUVB Nuvation Bio Inc.

P/E --
Forward P/E -99.166664
Price/Sales 14.483465
Beta 1.563
Div Yield --
Market Cap --

Company Analysis

Latest News

Nuvation Bio Raises $200 Million in Convertible Debt — But Why Now, With Half a Billion Already in the Bank?

Nuvation Bio Raises $200 Million in Convertible Debt — But Why Now, With Half a Billion Already in the Bank?

Shares of Nuvation Bio (NUVB) tumbled 11.8% to $5.70 on June 25 after the oncology company announced a $200 million convertible senior notes offering due 2032,...

🔴 NUVB is trading 11.8% down today after $200M convertible senior notes offering

NUVB is trading 11.8% down at $5.70 following the announcement of a $200 million convertible senior notes offering due in 2032. • The financing news has...

🔴 NUVB plunges 14.9% after announcing $200M convertible senior notes offering

• NUVB is trading at $5.50 (14.9% down) in pre-market action today. • The decline follows the company's announcement of a proposed $200.0 million Convertible...

🟢 NUVB is trading 5.5% up today, extending its multi-day momentum rally

NUVB is trading 5.5% up at $6.37, extending a multi-day rally as the stock continues its recent upward momentum. • The move follows several strong sessions,...

🟢 NUVB extends move to 5.3% up

NUVB is trading at $6.07, up 5.3% versus the comparison close of $5.76 during regular trading. This is a price-movement alert; no separate company-specific...

🟢 NUVB is trading 4.1% up today on oncology pipeline progress and trial advancements

NUVB is trading 4.1% up at $6.00, extending a multi-day rally driven by positive clinical and regulatory progress across its oncology pipeline. • The move...

🟢 Nuvation Bio Inc. is trading 5.3% up today after advancing IBTROZI and safusidenib trials and regulatory filings

Nuvation Bio Inc. is trading 5.3% up at $5.86 after announcing the advancement of clinical trials and regulatory filings for its lead candidates, IBTROZI and...

🟢 Nuvation Bio Inc. is trading 5.9% up today as it rebounds from post-rally consolidation

Nuvation Bio Inc. is trading 5.9% up today at $5.04, rebounding after a brief pullback and consolidation phase earlier this week. • The stock is regaining...

🔴 Nuvation Bio Inc. is trading 6.7% down today on profit-taking following a recent analyst-driven rally

Nuvation Bio Inc. is trading 6.7% down at $4.60 in pre-market action as the stock undergoes consolidation following a sharp rally earlier in the week. • The...

🔴 Nuvation Bio Inc. is trading 5.5% down today on profit-taking following a sharp post-upgrade rally

Nuvation Bio Inc. is trading 5.5% down at $4.66 as the stock undergoes consolidation following a significant rally driven by analyst optimism. • The stock...

🟢 Nuvation Bio Inc. is trading 13.3% up today as RBC Capital hikes price target to $20

Nuvation Bio Inc. is trading 13.3% up at $5.44, rebounding sharply from last week’s pullback as momentum continues following a major analyst upgrade. • RBC...

Nuvation Bio Pulls Back After RBC's Blockbuster $20 Target — Can a Brain Cancer Drug Justify a 4x Rally?

Nuvation Bio Pulls Back After RBC's Blockbuster $20 Target — Can a Brain Cancer Drug Justify a 4x Rally?

Shares of Nuvation Bio (NUVB) are slipping further in pre-market trading at $4.73, down 1.9%, as profit-taking extends following one of the most aggressive...

🔴 Nuvation Bio Inc. is trading 5.5% down today as it pulls back from a recent analyst-driven rally

Nuvation Bio Inc. is trading at $4.88 (5.5% down) today, giving back a portion of its sharp gains following a recent bullish analyst call. • RBC Capital...

🟢 Nuvation Bio Inc. is trading 0.4% up today after RBC Capital raised its price target to $20

Nuvation Bio Inc. is trading at $5.19 (0.4%) up today after RBC Capital raised its price target to $20, citing optimism around its glioma drug potential. •...

Nuvation Bio Price Target Raised to $20 by RBC Capital on Glioma Drug Potential

Nuvation Bio Price Target Raised to $20 by RBC Capital on Glioma Drug Potential

RBC Capital increased its price target for Nuvation Bio Inc. to $20.00 from $13.00. The firm reaffirmed its "Outperform" rating on the stock. The revision...

Nuvation Bio Surges 13% on Conference Buzz, but Can a Single Cancer Drug Justify the Climb?

Nuvation Bio Surges 13% on Conference Buzz, but Can a Single Cancer Drug Justify the Climb?

Shares of Nuvation Bio (NUVB) jumped 13.4% to $5.35 on Thursday, extending a rally that began after CEO David Hung and CFO Philippe Sauvage delivered a...

🟢 Nuvation Bio Inc. is trading 13.4% up today after positive Jefferies conference commentary

Nuvation Bio Inc. is trading 13.4% up today at $5.35, extending momentum following management's participation in a fireside chat at the Jefferies Global...

🟢 Nuvation Bio Inc. is trading 7.94% up, likely boosted by positive commentary at Jefferies Healthcare Conference

Nuvation Bio Inc. (NUVB) is trading 7.94% higher at $5.09 in live trading, with the upward momentum appearing to be driven by investor sentiment following a...